Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KAN-001
- Development stage
- Preclinical
- Lead developer
- Kanvas Biosciences
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
KAN-001 is a preclinical, fully defined Live Biotherapeutic Product (LBP) developed by Kanvas Biosciences. It is composed of dozens of bacterial strains originally isolated from a cancer patient who achieved a complete response to PD-1 inhibitor therapy. KAN-001 is designed to modulate the gut microbiome to enhance the host's immune system and improve the efficacy of immune checkpoint inhibitors (ICIs) for cancer patients who are resistant to such treatments. [2, 4, 6] The company is advancing KAN-001 towards an Investigational New Drug (IND) application, with a Phase 1 clinical trial planned for patients with non-small cell lung cancer (NSCLC).
Beyond the preview
Go deeper on KAN-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KAN-001.